{"filings":[{"id":174560,"accession_number":"0001640334-25-000428","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives' Zeranovia weight loss product shows 5-7 lbs/week loss in dosage trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Participants lost 5–7 pounds per week in Zeranovia dosage trial.","Minimal side effects: mild GI discomfort manageable by increasing water intake or adjusting dosage.","All trial subjects requested to proceed to next phase, indicating high satisfaction.","Company advancing to dosage adjustments for next-stage clinical trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174559,"accession_number":"0001640334-25-000210","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2025-02-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BioAdaptives appoints Mark Frissora (ex-Hertz CEO) to board, Reed Harris (UFC exec) to advisory board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark Frissora, former Chairman/CEO of Hertz and Caesars Entertainment, appointed to Board of Directors on Feb 3, 2025.","Reed Harris, SVP of Athlete Development at UFC and founder of WEC, appointed to Advisory Board on Feb 6, 2025.","Harris will help launch Xcellera stem cell activator; clinical trial showed 268.8% increase in circulating stem cells in 28 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191523,"accession_number":"0001640334-24-001825","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives declares one-for-one stock dividend payable in January 2025","summary_kind":"llm","event_type":"dividend","confidence":"high","bullets":["One additional common share for each share owned as of the record date.","Record date projected for second week of January 2025; payment within 15 days.","CEO James Keener says dividend rewards shareholders and signals long-term growth.","Stock trades on OTC under ticker BDPT.","No fractional shares; matching shares distributed to all common stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191522,"accession_number":"0001640334-24-001796","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives gets IRB approval for human trial of weight management product Zeranovia","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IRB approved human clinical trial for Zeranovia, a weight management supplement.","First phase to confirm dosing and identify side effects; participant slots quickly filled.","CEO notes less than 1% of nutraceuticals undergo human trials; aims for scientific proof.","Trial managed by doctors in Las Vegas, NV; next stage open to more participants.","If successful, Zeranovia could compare favorably to synthetic GLP-1 and GIP treatments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191521,"accession_number":"0001640334-24-001769","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["8.01","7.01","9.01"],"status":"ready","headline":"BioAdaptives completes 1-for-300 reverse stock split effective Nov 21, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split reduces outstanding shares from ~1.23B to ~4.1M.","Split approved by shareholders on Sep 3, 2024; FINRA approved on Nov 20, 2024.","Company cites need to exit sub-penny trading, attract institutional investors, and support new company-owned products.","All new shares issued in book-entry form; fractional shares rounded based on decimal threshold.","Intended to be tax-free for U.S. federal income tax purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191520,"accession_number":"0001640334-24-001612","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives plans reverse stock split after shares balloon 6,530% in 5 years; CEO cites turnaround","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shares outstanding grew from 18.6M (Jan 2020) to 1.23B (June 2024), a 6,530% increase with no revenue growth.","Reverse split intended to lift stock from sub-penny range; ratio and effective date not yet specified.","CEO James Keener (since management change) leading turnaround with new product lines for human and animal health.","Company expects increased revenue and profitability from upcoming product launches through new distribution channels.","Draft letter prematurely published by website contractor error; this press release clarifies the planned reverse split."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225529,"accession_number":"0001640334-24-000864","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives appoints James Keener as new CEO and Chairman; Jacobs and Ellis resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Edward Jacobs resigned as Chairman and CEO; Robert Ellis resigned as director and President, both for personal reasons.","James Keener elected Chairman of the Board and appointed CEO, becoming sole officer and board member.","Keener brings turnaround and marketing experience, led fastest-growing company in Hawaii in 2019/2020.","Outgoing leaders state new focus on sales and distribution under Keener's leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225528,"accession_number":"0001640334-24-000767","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["4.01"],"status":"ready","headline":"BioAdaptives dismisses auditor BF Borgers after SEC permanent suspension; appoints Boladale Lawal & Co","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["SEC permanently suspended BF Borgers from practicing as accountants and PCAOB auditors on SEC filings, effective May 3, 2024.","BioAdaptives Board dismissed BF Borgers as independent registered auditor on May 8, 2024.","Appointed Boladale Lawal & Co as new independent auditor on May 11, 2024, for FY2024 audits and review of 2024 quarterly reports.","New auditor will also audit balance sheet as of Dec 31, 2023, and related statements for the year then ended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297709,"accession_number":"0001640334-23-000587","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2023-04-06T23:59:59+00:00","items":["5.02","5.03","9.01"],"status":"ready","headline":"BioAdaptives appoints Dr. Yaguang Liu to board and increases authorized shares to 1.25 billion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Yaguang Liu appointed to board effective April 5, 2023; holds 32 US patents on natural botanicals.","Authorized common stock increased from 750M to 1.25B shares; preferred shares authorized at 10M.","Amendment approved by board and majority shareholders on March 6, 2023, effective March 27, 2023.","Dr. Liu is founder of L.Y. Research Corp and has experience with FDA IND applications and clinical studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":371438,"accession_number":"0001640334-22-001241","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives sponsors COVID long-hauler survey; offers senior discount pricing","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Sponsors COVID long hauler survey with Dr. Regina Sutton; provides free PluriPain, PrimiLungs, PrimiSleep.","Senior discount reduces prices from $59.95-$69.95 to $29.95-$39.95; targets 75M+ seniors.","Nutraceutical market cited at $454.55B in 2021 with 9% CAGR; aims to expand market presence.","CEO notes 20% of COVID infections become long haulers; survey studies symptom relief."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390409,"accession_number":"0001640334-22-000252","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2022-02-03T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"BioAdaptives acquires exclusive option to buy oxygenated-water patent, forms MORO2 subsidiary","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive two-year option to purchase U.S. Patent 9,783,432B for $400,000.","Exclusive two-year license to use technology for developing oxygenated water products.","Wholly-owned subsidiary MORO2, Inc. formed to exploit the patent and tech.","Inventor Thomas J. Mohr to provide consulting services and assist in product development.","Company plans to start marketing efforts during 2Q 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":390408,"accession_number":"0001640334-22-000150","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2022-01-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives signs LOI to acquire U.S. Patent 9,783,432B for oxygenated water tech","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["LOI with inventor Thomas J. Mohr to acquire rights to patent covering enhanced-oxygen water.","Technology reportedly embeds oxygen molecules in water for prolonged aerobic benefit.","CEO Edward Jacobs states the tech could complement existing Lung Armor product line.","Final terms involve options, licenses, consulting; consideration includes cash, royalties, warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408425,"accession_number":"0001640334-21-003192","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2021-12-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives enters marketing agreement for LungFlute medical device; plans LungArmor package","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Marketing agreement with Acoustic Innovations LLC for LungFlute™ OscPEP device; rights in US, Canada, and other approved regions.","Device is FDA-cleared, creates low-frequency acoustic energy to loosen mucus; used in $800K TB trial in Africa.","BioAdaptives to market device as LungCleanser™ combined with PrimiLungs™ supplement as LungArmor™ package.","No financial terms of the agreement disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427385,"accession_number":"0001640334-21-002041","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2021-08-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BioAdaptives partners with Stanford professor to study PluriPain for Gadolinium Deposition Disease pain","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Collaboration with Stanford's Prof. Lorrin Koran to research PluriPain for pain relief in Gadolinium Deposition Disease.","PluriPain used for analgesic/anti-inflammatory effects; no drug claims are made for treating the disease.","Gadolinium Deposition Disease is a rare disorder caused by MRI contrast agent, leading to chronic pain.","BioAdaptives' role is limited to providing PluriPain for Dr. Koran's research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427384,"accession_number":"0001640334-21-001630","cik":1575142,"company_name":"BIOADAPTIVES, INC.","ticker":"BDPT","form_type":"8-K","filed_at":"2021-07-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BioAdaptives Livestock Impact Division launches Ambassador Program for equine supplement marketing","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Ambassador Program provides affiliate marketing support, social media placement, and discounts for industry participants.","Products promoted: Equine All-in-One™ daily feed supplement and Canine Regen® canine supplement.","Program initially focused on breed-specific and sports organizations in Texas, plans to expand nationwide and overseas.","COO Charles Townsend to spearhead the outreach; company has revamped webpage livestockimpact.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":132095.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}